{"title": "PDF", "author": "PDF", "url": "https://www.maine.gov/dhhs/mecdc/infectious-disease/epi/airborne/documents/COVID-Webinar-3-4-2022.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "COVID -19 Vaccines & Therapies (Clinician Info Session) Isaac Benowitz, MD Maine CDC March 4, 2022COVID -19 VaccinesUpdates \u2014Vaccines FDA approved Moderna COVID -19 individuals 18+ years For people with moderate/severe immunocompromise: Clarified recommendations for 3 doses of mRNA vaccine + booster dose Shortened primary series -booster interval from 5 months to 3 months For people who got J&J vaccine: additional dose + booster dose (3 total) For all people who received a passive antibody product (such as a monoclonal antibody or plasma \u2014with/without immunocompromise) No longer necessary to delay vaccination after passive antibody treatment CDC: COVID -19 Vaccines for Moderately or Severely Immunocompromised People (https://www.cdc.gov/coronavirus/2019 - ncov/vaccines/recommendations/immuno.html ), Updated February 17, 2022CDC updates on COVID- 19 vaccines Extended interval between the1stand 2ndmRNA COVID -19vaccine Updates -19 use Summary ofcurrent recommendations forCOVID -19vaccination byage groupUpdated Guidance -However, tixagevimab/cilgavimab (EVUSHELD )should bedeferred foratleast was todefer for people ages 64years \u2014and especially males ages 12 through 39years \u2014may benefit from getting their second mRNA COVID - 19vaccine dose 8weeks after receiving their first dose Providers should (Pfizer -BioNTech) or4-week (Moderna) interval forpatients who: -Are at higher risk of having an inadequate response to the first mRNA vaccine dose People who aremoderately orseverely immunocompromised -19 rapid protection, such asduring high levels ofcommunity transmission -Children ages 5-11yearsGeneral Recommendations COVID -19primary series vaccination isrecommended foreveryone ages 5years and older in the United States forthe prevention ofCOVID -19 -This includes people both with and without underlying medical conditions -People with moderate or severe immunocompromise have additional considerations and need more doses than most people. In most situations, Pfizer -BioNTech or Moderna COVID -19 vaccines onset 2/25: EVUSHELD dose increased to 300mg + 300mg, recommendation for catch -up dose for those who only received 150mg + 150mg earlier 2/18 : Maine expands EVUSHELD for PrEP eligibility to Categories 1-4 2/11: FDA authorizes bebtelovimab, a new monoclonal antibody drugEvusheld EUA Update Initial Dosage and Administration 300 mg of tixagevimab and 300 mg of cilgavimab administered astwo separate consecutive intramuscular injections.Repeat Dosing for Patients who Previously Received 150 mg tixagevimab and 150 mg of cilgavimab 150 mgoftixagevimab and150mgof Formore information, seeFact Sheet results direct byanon-susceptible SARS- CoV-2 variant based onavailable information including variant susceptibility tothese drugs and regional variant Unclassified Public created new effective Feb. 11,2022 Q0222: Bebtelovimab Long thisincludes abeneficiary's home thathasbeen made provider - based to the hospital during thecovid -19public health emergency Short Descriptor: informationPrevalence of COVID- 19Variants Nationally HHS Resumption ofallocation willbe considered based on variant prevalence data and/or availability ofpatient level variant diagnostic testing. *Asdisease incidence declines andincoming supply increases tobetter meet demand, allocation strategies may transition later inMarch. Unclassified / For Public DistributionOutpatient Therapeutic Portfolio MonthlyN/A 50,000 Criteria Not hospitalized, no limitations Monoclonal Antibodiesfor PEP casirivimab + imdevimab (RGN) ** bamlanivimab + etesevimab (Lilly) ** **Not currently for use anywhere in theU.S. due totheprevalence ofOmicron.Mild toModerate have nothadaknown recent infected with SARS- CoV-2,AND Who have moderate tosevere immune compromise due toa medical condition or receipt of immunosuppressive medications ortreatments and may not mount an adequate immune response toCOVID -19vaccination, OR Forwhom vaccination withanyavailable COVID -19vaccine, according tothe approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID -19vaccine(s) and/or COVID -19vaccine component(s). Fact Sheet for co-packaged -19. individuals tosevere immune compromise1who may derive benefit from COVID -19 vaccination, should receive COVID -19vaccination. Inindividuals who have received aCOVID -19vaccine, EVUSHELDTMshould 2 weeks after lastvaccination. EVUSHELDTMmay only beprescribed bya healthcare provider licensed under state drugs foranindividually identified mg of tixagevimab and 150 mg 300 mg ofcilgavimab administered as two separate consecutive intramuscular injections. preferably onein each ofthe gluteal muscles, one after theotherContraindications and Precautions History of severe hypersensitivity reactions, including anaphylaxis, to anycomponent ofEVUSHELDTM. PrEP Maine Category 1 Lung Transplant Recipient (any time frame) Small Bowel Recipient (any time frame) Receipt of the following immunosuppressive medication within the past 12 months (for any condition, oncology and chronic lymphocytic leukemia, acute B -cell lymphoblastic leukemia, etc.) Multiple Myeloma, on active treatment with two or more agents Allogeneic Stem Cell Transplant, within 12 months of Transplant Autologous Stem Cell Transplant, within 6 months of Transplant Recipient of more than one active Transplant, different Organs (any time frame) Acute Myeloid Leukemia under Active Treatment Receipt of anti- CD19 or anti- BCMA (CAR) -T-Cell Immunotherapy, within six months of treatment Primary or Secondary T -Cell Immunodeficiency, including Severe Combined Immunodeficiency: Agammaglobulinemia (XLA/ARAG) (CVID) and similar phenotype with T -cell dysfunction Defects of Innate Immunity with predominant susceptibility to Viral Infections (e.g., WHIM Syndrome) Additional pediatric conditions (age 12 -17 years): Combined immune deficiencies with or without immune dysregulation (e.g., APDS, STAT3 GOF, ALPS) Primary immune regulatory disorders with or without immune deficiency (e.g., APECED, XIAP) High -risk or relapsed acute lymphoblastic leukemia/lymphoblastic lymphoma on intensive therapy (not maintenance therapy)Allogeneic stem cell transplant, more than 12 months since transplant Autologous stem cell transplant, more than 6 months since transplant Multiple myeloma, on maintenance therapy Any solid tumor, on active myelosuppressive chemotherapy Any solid organ transplant recipient not otherwise eligible in Category 1 Other chronic leukemias, on treatment Patients in lower categories with more than one qualifying condition Persons for whom vaccination with any available COVID -19 vaccine, according to the approved or authorized schedule, is not recommended, due to a history of severe adverse reaction, e.g., severe allergic reaction to a COVID -19 vaccine(s) and/or COVID- 19 vaccine component(s).Maine Category 2 Maine Category 3 Maine Category 4 Active treatment with high -dose corticosteroids (i.e., more than 20 mg prednisone or equivalent per day when administered for two weeks or longer) Active treatment with other biologic agents that are immunosuppressive or immunomodulatory, not otherwise listed in Categories 1 -2 Advanced or untreated HIV infection: HIV with CD4 less than 200/mm 3(if aged less than 14 years, CD4% less than 15%) AIDS- defining illness February 25, 2022 Maine Center for Confirmation viapositive 5-7days * ofsymptom onset Patient symptomatic butnotyetprogressed to require hospitalization oroxygen therapy (orincrease from baseline chronic 19,OR who require oxygen therapy duetoCOVID- 19, OR who require anincrease in baseline oxygen flowrateduetoCOVID- 19in those on chronic oxygen therapy duetounderlying non- COVID- 19 related comorbidity 1. CDC: Underlying Medical Conditions Associated with Higher Risk for Severe COVID -19: Information for Healthcare Providers (https://www.cdc.gov/coronavirus/2019- ncov/hcp/clinical -care/underlyingconditions.html ) *Patient eligibility with respect agents. Seeproduct factsheets forproduct -specific durations.US CDC: People with Certain Medical Conditions Cancer Chronic kidney disease Chronic liver disease Chronic lung diseases Cystic Fibrosis Dementia or other neurological conditions Diabetes (type 1 or type 2) Disabilities Heart conditions HIV infection Immunocompromised state (weakened immune system) US CDC: People with Conditions (https://www.cdc.gov/coronavirus/2019- ncov/need -extra -precautions/people -with- medical- conditions.html )Mental health conditions Overweight and obesity Physical inactivity Pregnancy Sickle cell disease or thalassemia Smoking, current or former Solid organ or blood stem cell transplant Stroke or cerebrovascular disease Substance use disorders Tuberculosis Children with medical complexityUS CDC: Underlying Medical Conditions Associated with Higher Risk for Severe COVID -19: Information for Healthcare Professionals Suggestive higher risk for severe COVID -19 outcomes Children with certain underlying conditions Overweight (BMI 25 kg/m2, but <30 kg/m2) Sickle cell disease Substance use disorders Thalassemia Mixed evidence Alpha 1 antitrypsin deficiency Asthma Bronchopulmonary dysplasia Hepatitis B Hepatitis C Hypertension*Higher risk for severe COVID -19 outcomes Cancer Cerebrovascular disease Chronic kidney disease* Chronic lung diseases: Interstitial lung disease, Pulmonary embolism, Pulmonary hypertension, Bronchiectasis, COPD (chronic obstructive pulmonary disease) Chronic liver diseases:Cirrhosis, Non -alcoholic fatty liver disease, Alcoholic liver disease, Autoimmune hepatitis Cystic fibrosis Diabetes mellitus, type 1 and Disorder (ADHD): Cerebral Palsy, Congenital Malformations (Birth Defects), Limitations with self -care or activities of daily living, Intellectual and Developmental Disabilities, Learning Disabilities, Spinal Cord Injuries, other disabilities [full list on webpage]Heart conditions (e.g., heart failure, coronary artery disease, or cardiomyopathies) HIV (human immunodeficiency virus) Mental health disorders:Mood disorders (including depression), Schizophrenia spectrum disorders Neurologic conditions limited to dementia Obesity (BMI 30 kg/m2)* Primary Immunodeficiencies Pregnancy and recent pregnancy Physical inactivity Smoking, current and former Solid organ or hematopoietic cell transplantation Tuberculosis Use of corticosteroids or other immunosuppressive medications US CDC: Underlying Medical Conditions Associated with Higher Risk for Severe COVID -19: Information for Healthcare Professionals ( https://www.cdc.gov/coronavirus/2019- ncov/hcp/clinical- care/underlyingconditions.html )* indicates underlying conditions for which there is evidence for pregnant and non- pregnant peopleComparisons of Recommended Outpatient days <7days <7days <5days Route of AdministrationPO IV IV IV PO Duration of Therapy 5days 1time 1 time 3days 5days drug- drug interactionsRequires IV infusion Requires IVinfusion-Lowefficacy -Notauthorized forage for mutageni city Limited supply Commerc ially availableGreater than Paxlovid *Adult or pediatric patient (age 12 and older weighing at least 40kg) with mild -to-moderate COVID -19 & athigh risk forprogression to severe disease - O2OR - Anincrease inbaseline home O2due to COVID -19 Yes Treatment of symptoms, Management per NIH & CDC GuidelinesNo Symptom onset within the past 5 -7 days? NoYesDoes patient have severe renal impairment (eGFR <30mL/min) hepatic impairment (Child mgnirmatrelvir taken 100mgritonavir twice daily for 5days Evaluate concomitant useofCYP3A inducers and medications with high dependency onCYP3A for clearance asthese may becontraindicated2,3 OR sotrovimab4500mgIVbegun ASAP within 7 days ofsymptom onset OR 2- 3begun ASAP within 7days of symptom onset If none of these therapeutics are available or clinically appropriate for patient treatment: Is patient age 18 or older AND possibility of pregnancy, if applicable, ruled out?No Yes Consider molnupiravir7800mg bymouth every 12h for5days begun ASAP within 5days of symptom onset Prescribers must review and comply with the mandatory requirements outlined inthe molnupiravir EUA7Yes Consider: sotrovimab4500 mg IV begun ASAP within 7 days of symptom onset OR bebtelovimab5175 mgsingle IVinjection ASAP within 7days of Guidelines to less than 40 kg or pediatric patients younger than 12years of age weighing at least 3.5 kg, with mild -to-moderate COVID -19 & at high risk forprogression tosevere disease Symptom onset within the past 7days? No Treatment of symptoms, Management per NIH & CDC GuidelinesYesPediatric patient (greater than 28days old) with severe renal impairment <30mL/min) OR Full-term neonate (7to28days old) with to 1 mg/dL?NoConsider remdesivir *1begun ASAP within 7days of symptom onset Pediatric than 12years weighing reporting isrequired Unclassified 38FDA has issued an EUA for the treatment of mild-to-moderate coronavirus disease (COVID -19) in adults (12 years of age and older weighing more than 40kg) who are at high risk for progression to severe COVID -19,including hospitalization and death, assoon as possible after only be prescribed for anindividual patient byphysicians, advanced practice registered nurses, and physician assistants thatarelicensed orauthorized under state lawtoprescribe drugs in the therapeutic class towhich Paxlovid belongs (i.e., anti -infectives). Fact Sheet twice daily for 5 days. eGFR <30mL/min: currently notrecommendedContraindications and Precautions History ofclinically oranyother components. Co-administration reactions1. Co-administration with potent CYP3A inducers may result in reduced nirmatrelvir plasma concentrations andpotential lossofvirologic response. The concomitant use of Paxlovid andcertain other drugs may result inpotentially significant drug interactions. Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred inpatients receiving ritonavir. Paxlovid use may lead to a risk ofHIV-1developing resistance to HIV protease inhibitors inindividuals criteria met Symptoms consistent -19 Symptom onset with5days * Nothospitalized 30 hepatic . This prescription fill by date is within 5 days from symptom onset andcomplies withthepatient eligibility criteria under theEUA. Unclassified 40Paxlovid Contraindications * *NOT COMPLETE LIST OF ALL DDI's. ALWAYS USE CLINICAL TOOLS/DDI CHECKER AND USE CLINICAL active ingredients (nirmatrelvir or ritonavir) or any other components of the product Drugs highly dependent on CYP3A4 forclearance and forwhich elevated concentrations nirmatrelvir or ritonavir concentrations may be associated with loss of AdministrationSotrovimab Authorization Unclassified 45FDA has issued an EUA to permit the emergency use of sotrovimab for the treatment of mild-to-moderate COVID ofageandolder of direct SARS- CoV-2viral testing, AND oWho are at high risk for progression tosevere COVID to COVID -19,OR oWho require an increase in baseline oxygen flow rateduetoCOVID -19(in those on chronic oxygen therapy duetounderlying age andolder weighing at least 40 kg): 500mgadministered as a single IV infusion over 30 minutes. Sotrovimab injection should beprepared byaqualified healthcare professional using aseptic technique. Sotrovimab should begiven as soon as possible after positive results of direct SARS- CoV-2viral testing andwithin 107 AdministrationBebtelovimab Authorization Unclassified 49FDA has issued an EUA to permit the emergency use of bebtelovimab for the treatment of mild-to-moderate COVID ofageandolder of CoV-2viral AND oWho are at high riskforprogression tosevere COVID -19,including hospitalization or death, AND oForwhom alternative COVID -19treatment options to COVID -19,OR oWho require an increase in baseline oxygen flow rateduetoCOVID -19(in those on chronic oxygen weighing at least 40 kg): 175mgadministered as a single IV injection (i.e., IVpush) over atleast 30seconds. Bebtelovimab injection should Bebtelovimab should andtherefore, should beadministered immediately. oIfimmediate administration is forapproximately 20 minutes prior to administration Attach thesyringe extension set. Prime theextension set. Administer theentire over atleast administered, flush theextension setwith0.9% Sodium Chloride to ensure delivery of the required dose.Veklury\u00ae(remdesivir) -Gilead Antiviral for IVInfusion Unclassified 52Veklury Product Information https:// www.vekluryhcp.com/Veklury\u00ae(remdesivir) Product Information Unclassified 53Prescribing Information FDA approved expanded use of Veklury\u00ae(remdesivir) to certain non-hospitalized adults and pediatric patients fortreatment of mild-to-moderate COVID 21, 2022), including: course of Veklury\u00ae(remdesivir) should be initiated as soon as possible after diagnosis of symptomatic COVID -19hasbeen made and within 7 days ofsymptom onset. Therecommended total oftreatment for Dosage: For adults and pediatric patients 12 years of age and older weighing more than 40kg: 200 mg on Day 1, followed by once -daily maintenance doses of 100 mg from Day 2 and Day 3 administered only via intravenous infusion over 30to120minutes 1 Forpediatric patients weighing 3.5kgto<40kg:5 mg/kg by2.5mg/kg -dose oftheproduct Hypersensitivity including infusion -related andanaphylactic reactions Increased risk of transaminase elevations Risk of reduced antiviral activity when coadministered with chloroquine phosphate orhydroxychloroquine sulfateMolnupiravir AdministrationMolnupiravir Authorization Unclassified 58Molnupiravir has been authorized by FDA under an EUA, for the treatment of mild- to- moderate COVID -19inadults who areathigh- riskforprogression tosevere including hospitalization or death, andforwhom alternative COVID -19treatment options authorized by FDA are not accessible orclinically appropriate. Notauthorized for: Patients lessthan 18years ofage Initiation due to COVID -19 Uselonger than 5consecutive days Molnupiravir may only beprescribed foranindividual patient by physicians, advanced practice registered nurses, andphysician assistants that are licensed orauthorized under state lawtoprescribe drugs in thetherapeutic class to which molnupiravir belongs (i.e., anti-infectives). Fact Sheet Care Providers ofMolnupiravir (https:// www.fda.gov/media/155054/download)Molnupiravir Unclassified 59Dosage and Admin istrati on 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days, with or without food. Not authorized for use for longer than 5 consecutive days.Contraindications and Precautions Nocontraindications have been identified based onthelimited available data onthe emergency useofmolnupiravir authorized under thisEUA. Not recommended for use during pregnancy and not authorized for use in patients under 18 years ofage. Formore information, see High-riskcriteria met Symptoms consistent withmild-moderate COVID -19 Symptom onset with 5 days * Not hospitalized duetoCOVID -19 Assessment pregnancy andbreastfeeding status (ifapplicable) Provide appropriate counseling potential useareliable method ofcontraception correctly from symptom onset and complies withthe patient eligibility criteria under theEUA.Molnupiravir Prescriber Requirements Unclassified 61AllPatients 1. Provide andforat least thelastdose Theprescribing provider and/or theprovider's designee must report allmedication errors andserious adverse events potentially related tomolnupiravir within 7calendar days from the healthcare provider's awareness oftheevent *How andwhere documentation occurs is atthediscretion oftheprescribing health care and their clinical site.Molnupiravir Prescriber Requirements Unclassified 62Individuals ofChildbearing Potential 1. Assess whether pregnant ornot Report oflastmenstrual period inanindividual who hasregular menstrual cycles, uses areliable method of contraception andconsistently pregnancy ofthepregnancy program agrees toparticipate inthepregnancy surveillance program andallows the prescribing healthcare provider todisclose patient specific information toMerck, theprescribing healthcare provider must aware ofthepregnancy surveillance program andencourage them to participate should they become pregnant Review contraception requirements permolnupiravir Providers Fact Sheet (https:// www.fda.gov/media/155054/download) *How and where documentation occurs is at thediscretion ofthe prescribing health care provider andtheir clinical site.Onset of Clinical visit and Confirmed Treatment symptoms diagnostic test positive testExample of timeline which would fulfill EUA requirementsPathway toTreatment: Patient with Confirmed COVID- 19Infection Strong and HCP to getright treatment toright patients atright time Fast testing turnaround needed, toefficiently identify positive tests and schedule for treatmentEarly administration of treatment needs fast testing turn- around and patient scheduling Planning required for \"Test toTreat\" models 3 days post symptomonset 24 hours postdiagno stic testASAP post positivetest result Treatment required within 5 to 10 days of symptom onset Testing sites should recommend COVID+ patients that are high risk confer with their HCP on potential suitability forTx *Please reference EUA factsheet for specific treatment guidelines including recommended treatment window Unclassified 63<Day10formAbs; <Day5forOralAV Time Day0 Time between infection &testvaries Rapid tests = same day results Labtests = 1-2daysAsfastassame day Asfastassame day Patient infected /exposed / expects exposurePatient tested andreceives resultsPatient receives treatmentPatient evaluated and prescribed treatment4 3 2 1Patient journey Potential awareness leakage pointsPatient asymptomatic Patient does not inform close contacts ofpotential exposurePatient unaware of / doesn't believe inneed totest of time Patient unaware oftime waits toolong tofill Rx Provider unaware ofdrug or reluctant to prescribe No rapid test available at sitePatient cannot access provider consult Patient can't access product (e.g., cannot find site, site does not have product, delivery takes toolong)Potential access leakage points Labtakes toolong returning results Minimize Unclassified 64COVID- 19Test toTreat withCOVID -19who areat andtransmission through early diagnosis andtreatment of high- risk individuals, thereby reducing morbidity andmortality caused byCOVID -19 Reduce disparities inCOVID -19outcomes through equitable strategies thatprioritize access to tests and reduce barriers to treatments for high- risk individuals disproportionately impacted by COVID -19 Unclassified 65Test toTreat Overview Test toTreat efforts aimtoaddress challenges with patients obtaining therapeutics, including : Consumer knowledge of\"test to treat\" guidance Access to tests upon symptom onset Access to healthcare provider (or treatment site for mAbs) within timeframe for treatment effectiveness Provider knowledge of and comfort level withprescribing therapeutics Equitable distribution oftherapeutics, especially Strategy: health literacy. Ensure Access toTests forearly diagnosis, withaspecific focus on high- riskindividuals. Facilitate toCare after ofTest toTreat: Facilitate early diagnosis and rapid linkage to treatment for individuals with COVID -19 who are at high risk for complications , thereby reducing morbidity and mortality caused byCOVID -19andreducing disparities inCOVID -19outcomes. Requirements bypatient andprovider of current testing andtreatment guidance andavailability. Rapid access totestandresults after symptom onset. Timely access toahealthcare provider forevaluation and prescription.* Timely access to medication (within afewdays after symptom onset.) *Different requirement for mAbs Unclassified 70Test toTreat Initiative Promote and support a variety of existing and new pathways for increased public and provider awareness, rapid access totests, and/or linkage totreatment, including: Public education Ensuring withstates/territories tosupport efforts re:distribution to high priority locations Prioritize other settings inwhich end-to-endtesttotreat model canbeprovided and/or disease burden ishigh Ongoing efforts toincrease supply oftherapeutics Exploring further opportunities for telehealth and other options for linkage to care and treatment Unclassified 71COVID -19 Therapies in MaineNIH: COVID -19Treatment Guidelines When There AreLogistical orSupply Constraints Interim statement to provide guidance on which individuals might receive the greatest benefit from anti-SARS- illness individuals who arenotexpected Statement onPatient Prioritization forOutpatient TherapiesNIH Risk Group Prioritization Criteria The Panel prioritized the following risk groups for anti -SARS- CoV-2 mAb therapy based on Age, Vaccination status, Immune status , and Clinical risk factors For a list of risk factors, see the CDC webpage Underlying Medical Conditions Associated with High Risk for Severe COVID -19 The CDC website COVID- 19 Vaccines for Moderately or Severely Immunocompromised People provides a list of moderate and severe immunocompromising conditions. If supplies cannot be provided to all moderately to severely immunocompromised individuals because of logistical constraints or supply limitations, the Panel suggests prioritizing their use for those who are least likely to mount an adequate response to COVID- 19 vaccination or SARS -CoV-2 infection and who are at risk for severe Duration Start timing Access* Supply Offer to Paxlovid Oral 5 days 0-5 days after symptom onsetPharmacies, Hospitals, Clinics Very good Maine Tiers 1 -3 sotrovimab IV 1 day 0-7 days after symptom onsetHospitals, Clinics Very good Maine Tiers 1 -3 bebtelovimab IV 1 day 0-7 days after symptom onsetHospitals, Clinics Very good Maine Tiers 1 -3 remdesivir IV 3 days 0-7 days after symptom onsetHospitals, Clinics Excellent Maine Tiers 1 -3 molnupiravir Oral 5 days 0-5 days after symptom onsetPharmacies, Hospitals, Clinics Very good Maine Tiers 1 -3March 4, 2022 Maine Center for Disease Control and Prevention *For information on sites offering treatments in Maine, see the COVID -19 Treatment in Maine patient information webpage . (https://www.maine.gov/dhhs/mecdc/infectious -disease/epi/airborne/coronavirus/covid19 -treatment.shtml )Recommended Prioritization for COVID -19 Therapeutics Maine Tier 1 Maine Tier 2 *Unvaccinated refers to an individual who has not received 2 doses of an mRNA vaccine or 1 dose of the J&J vaccine. Vaccinated refers to an individual who received 2 doses of an mRNA vaccine or 1 dose of the J&J vaccine. Vaccinated individuals who have not received a vaccine booster dose are likely at higher risk for severe disease than those w ho are boosted, and providers may choose to prioritize such patients for treatment. **Clinical risk factors: some of the most important Underlying Medical Conditions Associated with High Risk for Severe COVID -19 (US CDC) include cancer, cardiovascular disease, chronic kidney disease, chronic lung disease, diabetes, immunocompromising conditions or receipt or immunosuppressive medications, obesity (BMI 30), pregnancy, sickle cel l disease. ***Immunocompromising conditions: Moderately or Severely Immunocompromised People (US CDC) include people who have been receiving active cancer treatment for tumors or cancers of the blood, received an organ transplant and are taking medicine to suppress the immune system, received a stem cell transplant within the last 2 years or tak ing medicine to suppress the immune system, moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott -Aldrich syndrome), advanced or untreated HIV infection, or active treatment with high- dose corticosteroids or other drugs that suppress the immune response.++Congregate facility : Includes persons living in nursing homes, assisted living facilities, jails prisons, and homeless shelters who do not meet higher -level criteria. Maine Tier 3March 4, 2022 Maine Center for Disease Control and Prevention In the setting of limited supply of therapeutics, prioritize use of treatments as follows: Unvaccinated* or V accinated *, 75+ yearsModerately/Severely Immunocompromised*** Unvaccinated, Pregnant+Unvaccinated*, 50+ years, 1+ clinical risk factors** Residing in a c ongregate facility++Unvaccinated* or Vaccinated*, 2 + risk factors**Vaccinated*, 65+ years, 1+ clinical risk EUA or prescriber informationUnvaccinated*, 65+ years+Pregnant : Treat all pregnant COVID -19 patients who are unvaccinated. Also consider treatment in the postpartum period. Consider treating vaccinated persons with other risk factors. Avoid use of antivirals if other drugs are available.NIH: Preference Based on Efficacy and Convenience of Use 300 mg with RTV 100 mg PO twice daily for 5 days eGFR 30 to <60 mL/min: Nirmatrelvir 150 mg with RTV 100 mg PO twice daily eGFR <30 mL/min: Not Severe Not recommended5 days Sotrovimab SOT 500 mg as a single IV infusion 10 days Remdesivir RDV 200 mg IV on Day 1, followed by RDV 100 mg IV once daily on Days 2 and 3b,c7 days Molnupiravir Molnupiravir 800 mg PO twice daily for 5 days 5 days aPer EUA criteria or clinical trial entry criteria. bAn eGFR <30 mL/min at screening or <90 days before screening was considered an exclusion criterion in the outpatient RDV study PINETREE, but only if a participant's weight was <48 kg. See the Remdesivir section for a discussion of RDV use in patients with renal impairment. cIf RDV is administered to patients who have a new or increasing need for supplemental oxygen but who are discharged from the EDbecause hospital resources are limited and inpatient admission is not possible, the total duration of therapy is 5 days. Key: ED = emergency department; eGFR = estimated glomerular filtration for the Drugs Recommended for High- Risk, Nonhospitalized Adults With Mild to Moderate COVID -19, Listed in Order of Preference Based on Efficacy and Convenience of UseSelection Considerations for Clinical Options Order Drug Effectiveness (hosp /death)Eligibility * Start withinBenefits Challenges #1 Paxlovid 88% 12 years (40 kg) 5 days Oral drug Drug -drug interactions Severe shortage #2 sotrovimab 85% 12 years (40 kg) 7 days Single treatment IV infusion x1 day Severe shortage #3 bebtelovimab Unknown 12 years (40 kg) 7 days Single treatment IV infusion x1 daySevere shortage #4 remdesivir 87% 12 years (40 kg) <12 y, 3.5- 40 kg **7 days Abundant supply IV infusion x3 daysInsuranceTransportation #5 molnupiravir 30% 18 years 5 in pregnancyModerate shortage *Paxlovid, sotrovimab, bebtelovimab, and molnupiravir are only available under FDA EUA and must be prescribed in accordance w ithFDA EUA for individuals diagnosed with COVID -19 and mild/moderate illness at high risk for developing severe disease. Off -label prescribing is not available for drugs that are available under FDA EUA. **Remdesivir is FDA- approved for non- hospitalized patients 12 years and older (40 kg and up). It is also available under FDA EUA for patients <12 years old (3.5 to 40 kg).March 4, 2022 Maine Center for Disease Control and PreventionSelection Considerations for Clinical OptionsMarch 4, 2022 Maine Center for Disease Control and Prevention Drug category Drugs available Considerations Oral antiviralsPaxlovid (PO) molnupiravir (PO)\"Strategic niche\" for outpatient treatment of COVID- 19 similar to that of oseltamivir (Tamiflu) for influenza: prescribe within the first 5 days after symptom onset, possibly without in -person visit; consider molnupiravir for renal impairment, hepatic failure, or certain drug -drug interactions IV monoclonalssotrovimab (IV) bebtelovimab (IV)Greater acceptance, can be used within 7 days after symptom onset; limited based on need for an infusion site, fewer locations in the state IV antivirals remdesivir (IV) IV infusion x3 days that must be covered by patient's own insuranceMonoclonal antibody therapy is available at selected hospital, outpatient, and other locations , in limited supply, across MaineOral therapies (Paxlovid and molnupiravir) currently available in limited quantities at selected Maine retail pharmacy locations : Walmart (8 stores) Hannaford (2 stores) Also available at some federally -qualified health centers (for established patients) Penobscot (Bangor) Remdesivir is now FDA- approved for outpatient treatment, and available at some monoclonal antibody sitesMonoclonal antibody therapy is available at selected hospital, outpatient, and other locations , in limited supply, across MaineOral therapies (Paxlovid and molnupiravir) currently available in limited quantities at selected Maine retail pharmacy locations : Walmart (8 stores) Hannaford (2 stores) Also available at some federally -qualified health centers (for established patients) Penobscot (Bangor) HealthReach (Waterville)Treatment Remdesivir is now FDA- approved for and available at some monoclonal antibody sitesMonoclonals the definition 'vital signs' (VS): Temp, HR, RR, blood pressure, O2 sat Dose 1 : VS before infusion VS at 15 mins (halfway through 30 min infusion) VS at 30 mins (end of infusion) VS after 15 min monitoring (prior to discharge) Total of 4 sets Dose 2 & 3 : VS before infusion VS at 15 mins (halfway through 30 min infusion) VS at 30 mins (end of infusion, this serves as the prior to discharge VS as well) Total of 3 setsKey resources Maine CDC: COVID-19 provider information (https://www.maine.gov/dhhs/mecdc/infectious - disease/epi/airborne/coronavirus/providers.shtml ) Maine CDC: COVID-19 Treatment in Maine for patients) (https://www.maine.gov/dhhs/mecdc/infectious - (COVID- 19) | US CDC US CDC COVID- 19 Vaccines Clinical Considerations Maine COVID -19 Vaccines (maine.gov) Maine COVID -19 Vaccines FAQ Maine COVID -19 Vaccination Sites HHS/ASPR Website mAbs https://combatcovid.hhs.gov/ EUA Health Care Provider Fact Sheet FDA Provider Fact "}